Therapy for Women in Biotech and Pharma Leadership
In my work with women leading biotech and pharma, I see the weight of science, business, and regulation pressing in all at once. You’re navigating high-stakes decisions that affect lives and careers, while often feeling isolated in your role. This therapy is designed to help you reconnect with your purpose, manage relentless pressure, and find your voice in the boardroom and beyond.
- The Moment of Truth: Navigating Phase III Data Readouts
- The Triple Pressure: Science, Business, and Regulation
- Breaking the Glass Beaker: Women Leading in a Male-Dominated Industry
- The Long Game: Managing the Emotional Toll of Drug Development
- Identity Shift: From Clinician to Executive
- Impostor Syndrome and Executive Presence
- Building Resilience Amid Uncertainty
- Therapeutic Approaches Tailored for Biotech and Pharma Leaders
- Frequently Asked Questions
The Moment of Truth: Navigating Phase III Data Readouts
The conference room holds its breath. The hum of quiet conversation fades as all eyes fix on her. Scientists lean forward, investors clutch their notes, and the board joins the call, waiting for the verdict. She slides the envelope across the table—or clicks open the encrypted file on her laptop—and the data appears. The efficacy numbers aren’t a clear win. They’re not a clear loss either. Just borderline.
Her heart thuds in her chest. She knows that the next thirty seconds will shape the future of this program—and the careers tethered to it. The air feels thick, almost electric with anticipation. The polished glass walls reflect the tension, the flicker of screens, and the slight tremor of her hand.
In my work with clients in biotech and pharma leadership, I see how this moment—so public and so charged—belies a deeper, quieter storm. These women carry the weight of scientific discovery, business strategy, and regulatory demands all at once. They’re navigating a world where the stakes are measured not just in millions of dollars, but in years of hope, countless hours of labor, and the lives of patients waiting on the other side of the data.
Only 18% of biotech CEOs and 30% of pharma C-suite roles are held by women, amplifying the pressure to prove themselves in every decision. The drug development timeline stretches across a decade, with a 90% chance of failure in clinical trials. Many physician-scientists who’ve stepped into these roles speak of a profound identity loss—trading direct patient care for boardroom presentations, regulatory battles, and investor relations. It’s a high-wire act with no safety net, and the compensation, often between $300K and $800K+, reflects the gravity of the responsibility they shoulder.
What Is Scientific Identity Grief?
In my work with women leading in biotech and pharma, I often see a deeply personal form of loss I call scientific identity grief. This grief emerges when driven women who trained and thrived as clinicians or researchers transition into leadership roles. They leave the lab bench or clinic with hopes of making a broader impact, yet find themselves distanced from the very science and patients that fueled their passion. It’s a unique kind of mourning for a self that feels left behind amid new responsibilities in business strategy, regulatory oversight, and stakeholder management.
What I see consistently is that this grief isn’t just about career change — it’s about losing a central part of identity. These women once defined themselves by their expertise in biology, patient care, or experimental design. Now, their days are filled with boardroom negotiations and compliance discussions. The molecule they spent years advancing might still be years from approval, or worse, fail entirely after a decade of investment. This can trigger feelings of invisibility, frustration, and questioning of purpose despite impressive compensation and status.
Women in biotech and pharma leadership navigate a rare pressure cooker. Only 18% of biotech CEOs and 30% of pharma C-suite roles are held by women, making this journey isolating. The drug development timeline itself adds a unique stressor: working for five to ten years on a single molecule that has about a 90% chance of not making it through clinical trials. The stakes are high, and the emotional labor is intense. What I hear from clients is a longing to reconnect with their scientific curiosity and the patients who originally motivated them, even while managing the demands of executive leadership.
SCIENTIFIC IDENTITY GRIEF
Scientific identity grief is the mourning experienced by clinician-scientists who transition into leadership roles and lose connection with their original scientific or clinical self. This concept is informed by research on professional identity loss by Dr. Sarah L. Krein, PhD, associate professor at the University of Michigan School of Nursing, who explores identity shifts in healthcare professionals.
In plain terms: You’re grieving the part of you that loved being hands-on in science or patient care. Even though you’re leading, a part of you feels left behind, and that’s okay to feel.
The Neurobiology of Leadership Stress: When Science Meets Survival
In my work with driven women leading biotech and pharma companies, I see how the brain and body respond to the unique pressures they face. These leaders operate at the crossroads of science, business, and regulation — a combination that activates stress pathways in ways few other roles do. Stephen Porges, PhD, Distinguished University Scientist at Indiana University and originator of Polyvagal Theory, explains how the autonomic nervous system modulates our responses to safety and threat. Leaders juggling complex decision-making under regulatory scrutiny often experience heightened sympathetic nervous system activation, which can leave them stuck in a chronic state of “fight or flight.” This constant arousal impacts everything from focus and creativity to emotional regulation and resilience.
What I see consistently is the toll of “regulatory hypervigilance” — when the nervous system remains on edge, anticipating threats from every boardroom and FDA interaction. This hyper-alert state is exhausting and can impair the ability to engage socially and lead with empathy. Christina Maslach, PhD, social psychologist at UC Berkeley who defined the three dimensions of burnout, highlights how prolonged stress without adequate recovery leads to emotional exhaustion, depersonalization, and reduced personal accomplishment. For women in biotech and pharma leadership, this burnout often intertwines with identity challenges, especially when they’ve transitioned from clinician or scientist roles to executive positions.
This brings me to a neurobiological phenomenon I frequently encounter: scientific identity grief. Bessel van der Kolk, MD, psychiatrist and trauma researcher at Boston University School of Medicine and author of The Body Keeps the Score, shows how identity loss can trigger deep emotional pain because it touches on core self-concept and meaning. Women leaders who left patient-facing roles to “have more impact” often mourn the loss of their clinician or researcher selves. The brain’s limbic system—which governs emotion and memory—holds onto this grief, sometimes unconsciously influencing mood and motivation. Understanding this helps me tailor therapy that honors both the science-driven mind and the emotional heart.
Finally, the drug development timeline itself is a neurobiological stressor. Working 5-10 years on a single molecule with a 90% failure rate means women leaders’ self-worth can become tied to unpredictable outcomes. This “outcome dependence” creates a feedback loop where success or failure in clinical trials triggers intense emotional responses rooted in the brain’s reward and threat centers. Recognizing these patterns allows us to cultivate strategies that promote self-compassion and sustainable leadership identity beyond trial results or regulatory wins.
REGULATORY HYPERVIGILANCE
A heightened state of nervous system alertness calibrated to anticipate and respond to regulatory threats, often seen in leaders managing complex compliance environments. This concept is informed by Polyvagal Theory, developed by Stephen Porges, PhD, Distinguished University Scientist at Indiana University.
In plain terms: Your body stays on high alert, expecting challenges and risks from every meeting or decision, making it hard to relax or feel safe even when things are going well.
TAKE THE NEXT STEP
You don’t have to keep carrying this alone.
Book a complimentary 20-minute consultation to talk about what you’re experiencing and whether therapy with Annie is the right fit.
When Science Meets Pressure: The Hidden Strain on Women Leaders in Biotech and Pharma
In my work with women leading in biotech and pharma, I see a distinct kind of tension that’s often invisible to outsiders. These women don’t just navigate complex corporate hierarchies — they carry the weight of scientific discovery, patient hope, and regulatory demands all at once. It’s rare to find a role where the stakes feel so directly tied to human lives, yet where the path is littered with uncertainty and risk. With the odds stacked — a 90% failure rate in clinical trials — the emotional toll is relentless. You’re not just managing a team; you’re shepherding years of work that could fall apart overnight.
What I see consistently is the unique identity strain physician-scientists turned executives experience. They’ve stepped away from the clinic, hoping to make a broader impact, only to find themselves entrenched in endless boardrooms and compliance checklists. The patients who once fueled their passion can feel miles away, replaced by quarterly reports and investor calls. This disconnect can spark deep frustration and a sense of loss that’s hard to voice in a culture that prizes resilience and results.
The gender landscape adds another layer. With women holding only 18% of biotech CEO roles and 30% of pharma C-suite positions, many feel the quiet pressure of representing “all women,” carrying an unspoken burden to prove their worth. The compensation might be high, but it rarely buys relief from the constant vigilance and self-doubt that creep in behind closed doors.
Take Elara, VP of Clinical Development, for example. It’s 7:30 a.m. in her sleek Cambridge office, the city just waking up outside the floor-to-ceiling windows. She’s preparing for a regulatory briefing, her calendar packed back-to-back. Her phone buzzes—a message from a patient advocacy group thanking her for the new trial design, a rare moment that softens her hardened exterior. Yet as she looks out over the skyline, the hum of the city contrasts sharply with the quiet ache inside her. Despite the accolades, Elara feels the weight of every molecule’s risk, the years invested, and the distance from the bedside. She closes her eyes briefly, the facade slipping for just a moment—wondering if the impact she sought still feels real.
Navigating Identity Loss Amidst Scientific Ambition
In my work with clients who lead in biotech and pharma, I often see a profound tension between past and present selves. Many women enter leadership roles driven by a deep commitment to science and patient care, only to find their days dominated by regulatory hurdles, investor meetings, and corporate strategy. This shift can trigger a unique form of grief — mourning the loss of the clinician or researcher identity that once defined them. It’s not just about a job change; it’s about feeling disconnected from the very purpose that fueled their ambition.
This identity shift can stir complex emotions: frustration, disillusionment, and an aching sense of invisibility. What I see consistently is how this grief compounds under the weight of imposter syndrome and perfectionistic drives common among women in these roles. Their self-worth often feels tied to outcomes beyond their control, like trial results or market approvals. That makes setbacks feel intensely personal, even though drug development timelines and scientific discovery are inherently uncertain.
Regulatory hypervigilance also plays a significant role here. Women in leadership carry a nervous system finely tuned to anticipate threats—not only to their projects but to their careers and reputations. This constant state of alertness can exhaust emotional resources and limit space for self-compassion. The challenge becomes balancing this hyperawareness with the need to hold onto a coherent sense of self beyond external successes or failures.
“We don’t yet know, above all, what the world might look like if children were to grow up without being subjected to humiliation…”
Alice Miller, For Your Own Good
SCIENTIFIC IDENTITY GRIEF
Scientific identity grief describes the mourning process experienced by clinician-scientists who transition from direct patient care or research into leadership roles, losing connection to the core professional identity that motivated them. This concept is described by Elisabeth Kübler-Ross, MD, psychiatrist and pioneer in grief studies, adapted here for professional identity transitions.
In plain terms: You’re grieving the loss of the scientist or clinician part of yourself that made your work feel meaningful, even as you take on new roles that demand different skills and focus.
Both/And: the executive who can navigate an FDA advisory committee
In my work with driven women in biotech and pharma leadership, I see a powerful tension that often goes unspoken. You’re both the executive who can confidently navigate an FDA advisory committee and the woman who misses the days when she could help one patient at a time. This Both/And framework honors the complexity of your experience instead of forcing you to choose between identities. It acknowledges the unique pressures you carry at the intersection of science, business, and regulation.
You’ve spent years—sometimes decades—dedicating yourself to drug development, knowing that 90% of molecules won’t make it through clinical trials. The stakes are enormous, and the victories often feel abstract, wrapped up in boardroom strategies and regulatory approvals rather than in personal patient stories. Yet, the woman who once walked hospital corridors, providing direct care and comfort, still lives inside you. She’s not gone; she’s part of your leadership story. What I see consistently is that embracing this Both/And truth can unlock a deeper sense of meaning and self-compassion as you navigate these demanding roles.
Anouk is the Chief Medical Officer at a San Diego gene therapy startup. Today, she’s preparing for an FDA advisory committee meeting—a daunting blend of science, policy, and politics. Sitting in her glass-walled office, she reviews slides detailing clinical trial data, her mind sharp and focused. But as she pauses, her eyes drift to a photo on her desk: a young patient she once treated as a physician, smiling brightly. The memory hits her—the hands-on care, the immediate impact. A wave of longing washes over her, mingling with the pride she feels leading innovative therapies. In this moment, Anouk recognizes she doesn’t have to choose between these parts of herself. She’s both the executive shaping the future of medicine and the compassionate clinician who still holds her patients close. That realization brings a quiet steadiness, a reminder that her leadership carries the heart of her original purpose.
The Systemic Lens: Navigating the Invisible Weight of Leadership in Biotech and Pharma
In my work with clients leading in biotech and pharma, what I see consistently is how the industry’s very structure shapes their experience in ways that feel deeply personal but are anything but individual failings. The “fail fast” culture celebrated in biotech, borrowed from startup ethos, prioritizes rapid iteration over human impact. Yet, this approach overlooks the emotional and physical toll carried by the people—especially women—who steward these programs through years of uncertainty and pressure. When a drug candidate fails after a decade of effort, it’s not just an abstract setback; it’s a loss carried in the body and mind of the leader, expected to remain composed and resilient under the spotlight of regulatory scrutiny and board expectations.
Women in these roles occupy a unique space at the crossroads of science, business, and regulation, and that intersection creates compounded stressors. Only 18% of biotech CEO roles are held by women, while women fill about 30% of C-suite roles in pharma companies, according to the 2023 Women in Biotech Leadership Report by the Biotechnology Innovation Organization. This underrepresentation is more than a number—it reflects systemic barriers in advancement, implicit bias, and cultural assumptions about who “fits” leadership in these fields. Women often shoulder the invisible labor of managing team morale and emotional fallout after high-stakes failures, even as the system rewards a stoic “leadership presence.” This expectation to mask vulnerability while managing crisis is uniquely taxing and disproportionately placed on women, reinforcing gendered dynamics rather than alleviating them.
The drug development timeline itself is a crucible of stress. Leaders invest 5 to 10 years shepherding a molecule through preclinical and clinical stages, with a grim 90% failure rate in clinical trials (Tufts Center for the Study of Drug Development, 2022). This long arc of uncertain outcomes demands sustained emotional resilience and adaptability, yet the system offers little structural support for the cumulative burden. Women physician-scientists who transition into executive roles often describe a profound identity shift—a loss of direct patient care they once cherished, replaced by boardrooms and regulatory meetings. This shift not only challenges their professional identity but can deepen feelings of isolation and disconnection, especially when compensation ranges from $300K to $800K+ but doesn’t translate into emotional or psychological safety.
What I hear again and again is that the challenge isn’t a lack of personal grit or capability but the weight of an ecosystem designed to value rapid success and data-driven decisions over human complexity. The biotech and pharma leadership landscape demands more than scientific and business acumen—it requires navigating a system that often devalues emotional labor, particularly when performed by women. Recognizing this systemic framework is crucial for understanding the pressures these leaders face and why therapeutic support tailored to their unique intersectional stressors is essential—not a luxury or afterthought, but a necessary resource for sustainable leadership.
Charting Your Path to Renewal and Resilience
Healing for women leading in biotech and pharma means reclaiming your whole self amid the relentless demands of science, business, and regulation. In my work with clients, I see that healing isn’t about erasing the stress or rushing past the losses. It’s about gently unpacking the unique burdens you carry—the weight of long drug development timelines, the identity shifts from clinician to executive, and the persistent pressure to prove your place in a male-dominated space. Healing looks like reconnecting to the purpose that first drew you here while acknowledging the very real exhaustion and grief that come with the journey.
I often integrate EMDR (Eye Movement Desensitization and Reprocessing) to help process trauma linked to intense work stress and identity fragmentation. This modality allows you to rewire the way your brain stores distressing experiences, reducing their emotional charge. Alongside EMDR, I use Internal Family Systems (IFS) therapy to explore the different parts of you—the driven executive, the compassionate clinician, the anxious perfectionist—and help you develop a compassionate inner leadership that honors all these facets. Somatic Experiencing also plays a crucial role; by tuning into your body’s sensations, we can release stress that words alone can’t reach, restoring your natural capacity for calm and resilience.
My approach is deeply collaborative and tailored. We move at a pace that feels right for you, focusing on skills, insights, and self-compassion that you can carry into your demanding world. I offer a safe space where the pressure to perform can soften, and you can explore what’s truly alive inside you beneath the polished exterior. Together, we find ways to integrate your scientific mind with your emotional experience, allowing you to lead not just with expertise but with renewed authenticity.
On the other side of this work, what’s possible is profound. You can reconnect with the values that inspired you to enter biotech and pharma leadership in the first place. Your sense of identity can expand beyond the boardroom and regulatory meetings to embrace the full spectrum of your strengths and vulnerabilities. You might find that resilience feels less like a fight and more like a resource—something you cultivate rather than exhaust. Healing opens the door to a leadership style that’s not just sustainable but deeply fulfilling.
Thank you for reading this far—it takes courage to acknowledge the weight you carry and to consider the possibility of something different. You’re not alone in this journey. There’s a community of women who understand the unique challenges you face and a path forward that honors your complexity. When you’re ready, I invite you to reach out and take the next step toward connection and healing. You deserve a space where your whole self is seen, heard, and supported.
If any of this sounds familiar — if you’re reading this and thinking, “she’s describing my life” — you don’t have to keep carrying it alone.
You don’t have to keep managing this alone. If you’re ready to explore what therapy or coaching could look like for you, I’d be honored to hear your story.
Q: I left clinical practice for biotech leadership and now I’m doubting if I made the right choice. Is this normal?
A: Absolutely. What I see consistently with women who’ve transitioned from clinical roles to biotech or pharma leadership is a complex mix of pride and uncertainty. You moved from direct patient care to influence at a systems level, which can feel abstract or disconnected. It’s natural to question your path, especially when the impact isn’t as immediate. Therapy can help you explore these feelings and reconnect with your core motivations, so you feel clearer and more confident about your unique leadership journey.
Q: The failure rate in drug development is crushing my confidence. How can I cope with that?
A: Drug development’s failure rate—up to 90% in clinical trials—is brutal. Christina Maslach, PhD, social psychologist at UC Berkeley who defined burnout, highlights how persistent setbacks can erode self-worth and motivation. In my work with clients, we focus on separating the outcome from your value as a leader and scientist. It’s important to hold space for grief and frustration, while also identifying resilient strategies that keep you engaged without sacrificing your well-being.
Q: I feel like I’ve sold out by moving into leadership—is that imposter syndrome or reality?
A: Feeling like you’ve “sold out” often reflects imposter syndrome, especially for women navigating male-dominated biotech and pharma leadership. This feeling arises when your internal sense of worth clashes with external achievements and pressures. It’s not reality, but a psychological response to complex identity shifts and high expectations. Therapy can help you unpack these feelings, challenge unhelpful beliefs, and develop a more authentic, self-compassionate narrative about your success and impact.
Q: How do I manage leading a team through a failed trial when I’m grieving too?
A: Leading through loss while grieving yourself requires deep emotional stamina. What I see consistently is that women leaders benefit from carving out private spaces to process their grief, separate from their professional role. Balancing vulnerability and leadership is hard but essential. In therapy, we work on strategies to hold your own feelings without shutting down, so you can authentically support your team while honoring your own experience.
Q: My identity used to be ‘doctor.’ What is it now that I’m in biotech leadership?
A: This identity shift is profound. Many physician-scientist executives describe feeling untethered after leaving clinical work. Your identity now blends science, business, and leadership—roles that don’t always fit traditional definitions. Therapy offers a space to explore this evolving identity, integrate your past with your present, and find meaning in your expanded impact. It’s about crafting a new story that honors both your clinician roots and your leadership power.
Q: How do I schedule sessions, and what if my leadership role demands flexibility?
A: I understand how demanding biotech and pharma leadership schedules can be. I offer flexible session times, including evenings, to accommodate your availability. You can schedule directly through my secure online portal, making it easy to fit therapy into your busy week. If you need to reschedule, I ask for at least 24 hours’ notice to respect your time and mine. Therapy is designed to support your life, not complicate it.
Q: Is confidentiality guaranteed, especially given my high-profile role?
A: Confidentiality is a cornerstone of my work. I adhere strictly to all legal and ethical standards, including HIPAA regulations, to protect your privacy. Your sessions are a safe space where you can share openly without concern about information being disclosed. This protection is especially important for women in leadership roles within biotech and pharma, where discretion is vital to maintain professional boundaries and trust.
I’m the only woman in leadership at my company. Can therapy help with that isolation?
Yes, and this is one of the most important things therapy can address. The isolation of being the only woman in a leadership room isn’t just professional loneliness — it’s a nervous system state. Your brain is constantly monitoring for social threat, calibrating how much of yourself is safe to reveal, and performing a kind of code-switching that is cognitively and emotionally exhausting. Over time, this hypervigilance becomes your baseline, and you stop recognizing it as a stress response because it feels normal. In therapy, we work on recalibrating that baseline — helping your nervous system distinguish between environments that genuinely require guardedness and environments where you can actually rest. This distinction, once restored, changes everything about how you move through your professional and personal life.
How is therapy with a tech executive different from general executive therapy?
Tech culture carries specific psychological imprints that differ from other industries. The expectation of perpetual disruption means your nervous system never fully settles — there’s always the next product cycle, the next funding round, the next competitor emerging. The meritocratic narrative (“the best idea wins”) creates a particular kind of isolation when you discover that success also requires navigating politics, bias, and structural barriers. And the pace of change in technology means that the skills that got you here may not be the skills that keep you here, creating a chronic undercurrent of obsolescence anxiety that your peers in more stable industries don’t experience in the same way. I work with these specific dynamics rather than applying generic executive coaching frameworks that miss the texture of your actual experience.
Related Reading
WAYS TO WORK WITH ANNIE
Individual Therapy
Trauma-informed therapy for driven women healing relational trauma. Licensed in 10 states.
Executive Coaching
Trauma-informed coaching for ambitious women navigating leadership and burnout.
Fixing the Foundations
Annie’s signature course for relational trauma recovery. Work at your own pace.
Strong & Stable
The Sunday conversation you wished you’d had years earlier. 23,000+ subscribers.
Annie Wright, LMFT
LMFT · Relational Trauma Specialist · W.W. Norton Author
Helping ambitious women finally feel as good as their résumé looks.
Annie Wright is a licensed psychotherapist (LMFT #95719) and trauma-informed executive coach with over 15,000 clinical hours. She works with driven, ambitious women — including Silicon Valley leaders, physicians, and entrepreneurs — in repairing the psychological foundations beneath their impressive lives. Annie is the founder and former CEO of Evergreen Counseling, a multimillion-dollar trauma-informed therapy center she built, scaled, and successfully exited. A regular contributor to Psychology Today, her expert commentary has appeared in Forbes, Business Insider, Inc., NBC, and The Information. She is currently writing her first book with W.W. Norton.
